切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2020, Vol. 08 ›› Issue (01) : 6 -12. doi: 10.3877/cma.j.issn.2095-5820.2020.01.002

所属专题: 文献

实验研究

DNA修复基因在基于铂类药物化疗的非小细胞肺鳞癌患者中的预后价值
谢科杰1,(), 何红尔1, 王兴木1, 王美丹1, 吴东东1   
  1. 1. 312000 浙江绍兴,绍兴市人民医院 浙江大学绍兴医院
  • 收稿日期:2019-06-18 出版日期:2020-02-28
  • 通信作者: 谢科杰
  • 基金资助:
    绍兴市科技计划项目(2015B70043)

Prognostic value of DNA repair genes in non-small cell lung squamous carcinoma patients received platinum-based chemotherapy

Kejie Xie1,(), Honger He1, Xingmu Wang1, Meidan Wang1, Dongdong Wu1   

  1. 1. Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing Zhejiang 312000, China
  • Received:2019-06-18 Published:2020-02-28
  • Corresponding author: Kejie Xie
  • About author:
    Corresponding author: Xie Kejie, Email:
引用本文:

谢科杰, 何红尔, 王兴木, 王美丹, 吴东东. DNA修复基因在基于铂类药物化疗的非小细胞肺鳞癌患者中的预后价值[J/OL]. 中华临床实验室管理电子杂志, 2020, 08(01): 6-12.

Kejie Xie, Honger He, Xingmu Wang, Meidan Wang, Dongdong Wu. Prognostic value of DNA repair genes in non-small cell lung squamous carcinoma patients received platinum-based chemotherapy[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2020, 08(01): 6-12.

目的

了解DNA修复基因在接受以铂类药物为基础化疗的非小细胞肺癌(NSCLC)患者中不同病理类型的预后价值。

方法

应用免疫组织化学技术检测121例NSCLC铂类药物化疗患者石蜡包埋病灶组织中多聚ADP-核糖聚合酶基因1(PARP1),切除修复交叉互补基因1(ERCC1),错配修复同源型2基因(MSH2),乳腺癌易感基因1(BRCA1)表达状态。分析NSCLC患者DNA修复基因的表达与临床病理特征之间的关系。并通过生存分析判断DNA修复基因的表达在不同病理类型中NSCLC化疗患者中的预后价值及是否为独立的预后指标。

结果

ERCC1、PARP1、BRCA1、MSH2在非小细胞肺癌的表达均未显示与患者的性别、年龄、吸烟指数、临床TNM分期的相关性(P均>0.05)。在NSCLC腺癌组中ERCC1、PARP1、BRCA1、MSH2均不是判断预后的独立因素(P均>0.05)。鳞癌组中ERCC1、PARP1是预后判断独立因素(P=0.019,0.031)。

结论

ERCC1、PARP1是基于铂类药物化疗的非小细胞肺鳞癌患者独立的预后指标。

Objective

To explore the prognostic value of DNA repair genes in patients with different pathological types of non-small cell lung cancer (NSCLC) and were all received platinum-based chemotherapy.

Methods

Immunohistochemical technique was used to measure the expression levels of the following DNA repair genes: poly ADP-ribose polymerase gene 1 (PARP1), excision and repair of cross-complementing gene 1 (ERCC1), mismatch repair and homology type 2 gene (MSH2), breast cancer susceptibility gene 1 (BRCA1) in paraffin embedded lesions of 121 NSCLC patients received platinum-based chemotherapy. The relationship between the expression levels of DNA repair genes and clinicopathological features in NSCLC patients was analyzed. The prognostic value of DNA repair gene expression level in NSCLC patients with different pathological types and whether it is an independent prognostic index were determined by survival analysis.

Results

The expression of ERCC1, PARP1, BRCA1 and MSH2 in NSCLC was not correlated with gender, age, smoking index and clinical TNM staging (P>0.05). ERCC1, RARP1, BRCA1, and MSH2 were not independent prognostic factors in NSCLS adenocarcinoma patients (P>0.05). But ERCC1 and PARP1 were independent prognostic factors in NSCLS squamous patients (P=0.019, 0.031).

Conclusion

ERCC1 and PARP1 are independent prognostic markers of NSCLC SCC patients received platinum-based chemotherapy.

表1 4种DNA修复基因在NSCLC表达与临床特征之间的相关性
图1 4种DNA修复基因在NSCLC免疫组化结果示意图(40×)
图2 腺癌组中ERCC1、PARP1、BRCA1、MSH2的表达与生存分析
图3 鳞癌组中ERCC1、PARP1、BRCA1、MSH2的表达与生存分析
表2 腺癌及鳞癌中4种DNA修复基因表达与预后的单因素分析
表3 NSCLC术后辅助化疗鳞癌患者常见临床特征与预后的关系(单因素分析)
表4 术后辅助化疗患者鳞癌组COX多因素分析
1
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018,378(22):2078-2092.
2
Xie KJ, He HE, Sun AJ, et al. Expression of ERCC1,MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy[J]. Asian Pac J Cancer Prev, 2014,15(6):2591-2596.
3
Wallerek S, Sørensen JB. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA[J]. Eur Respir Rev, 2015,24(136):340-355.
4
Chen YY, Lin YJ, Huang WT, et al. Demethoxycurcumin-loaded chitosan nanoparticle downregulates DNA repair pathway to improve cisplatin-induced apoptosis in non-small cell lung cancer[J].Molecules, 2018,23(12).pii: E3217.
5
Apopa PL, Alley L, Penney RB, et al. PARP1 is up-regulated in non-small cell lung cancer tissues in the presence of the cyanobacterialtoxin microcystin[J]. Front Microbiol, 2018,9:1757.
6
丁剑午,唐罗勇,艾素芬,等. ERCC1、BRCA1、RRM1表达在晚期非小细胞肺癌个体化治疗中的前瞻性研究[J].中国当代医药,2017,32:56-58.
7
白娟,郑玲,李茨,等.联合检测ERCC1、BRCA1、RRM1表达在非小细胞肺癌选择化疗方案中的意义[J].现代肿瘤医学, 2016,21:3410-3413.
8
Pierceall WE, Olaussen KA, Rousseau V, et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses[J].Annoncol, 2012,23(9):2245-2252.
9
Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma[J]. J Thorac Oncol, 2011,6:244-285.
10
Pereira TC, Share SM, Magalhaes AV, et al. Can we tell the site of origin of metastatic squamous cell carcinoma? An immunohisto-chemical tissue microarray study of 194 cases[J]. Appl Immunohis-tochem Mol Morphol, 2011,19:10-14.
11
Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples[J]. Am J Surg Pathol, 2010,34:1805-1811.
12
Jin G, Kim MJ, Jeon HS, et al. PTEN mutations and relationship to EGFR,ERBB2,KRAS,and TP53 mutations in non-small cell lung cancers[J]. Lung Cancer, 2010,69:279-283.
13
Christopoulos P, Kirchner M, Endris V, et al. EML4-ALK V3, treatment resistance,and survival: refining the diagnosis of ALK+ NSCLC[J]. J Thorac Dis, 2018,10(Suppl 17):S1989-S1991.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[7] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[8] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[9] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[10] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[11] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[12] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[13] 张颖, 赵鑫, 陈佳梅, 李雁. 术前化疗对CRS+HIPEC 治疗腹膜假黏液瘤预后影响的meta 分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 826-835.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要